Latest / Community Health Media
Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC
A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment.
The conversation explores:
Why DB09 may replace the CLEOPATRA standard
The significance of 40+ month median PFS
Complete response rates and treatment durability
Managing ILD, fatigue, nausea, and alopecia
Maintenance therapy strategies
PATINA and HER2CLIMB-05 insights
Sequencing after T-DXd progression
Why “saving your best drug for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.